Compugen (CGEN) Expected to Release Earnings on Monday

Compugen (NASDAQ:CGEN) is anticipated to post its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $1.28 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%. The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. During the same quarter in the previous year, the business earned ($0.08) EPS. On average, analysts expect Compugen to post ($0.28) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Compugen Stock Down 0.3%

Shares of CGEN opened at $1.98 on Monday. The company has a market cap of $186.74 million, a P/E ratio of 5.21 and a beta of 2.85. Compugen has a fifty-two week low of $1.43 and a fifty-two week high of $3.23. The firm’s 50 day moving average price is $2.32 and its 200 day moving average price is $2.29.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CGEN shares. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Compugen in a research note on Monday, October 12th. Weiss Ratings upgraded shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Compugen presently has a consensus rating of “Buy” and an average target price of $5.00.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.